Activation of the hemostatic system during cardiopulmonary bypass

Anesthesia and Analgesia

Volumn 113, Issue 6, 2011, Pages 1319-1333

  Sniecinski, Roman M ^a   Chandler, Wayne L ^b,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ALBUMIN; ANTIFIBRINOLYTIC AGENT; ANTITHROMBOCYTIC AGENT; APROTININ; ARACHIDONIC ACID; BETA THROMBOGLOBULIN; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; BRADYKININ; D DIMER; DABIGATRAN ETEXILATE; FIBRIN; FIBRINOPEPTIDE A; GLYCOPROTEIN IB; HEPARIN; HIRULOG; KALLIKREIN; KININ; PADGEM PROTEIN; PHOSPHORYLCHOLINE; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREKALLIKREIN; SILOXANE; THROMBIN; THROMBOCYTE FACTOR 4; THROMBOCYTE RECEPTOR; TISSUE PLASMINOGEN ACTIVATOR;

BIOCOMPATIBILITY; CARDIOPULMONARY BYPASS; FIBRINOLYSIS; HEMODILUTION; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; KALLIKREIN KININ SYSTEM; KIDNEY DYSFUNCTION; LIVER BLOOD FLOW; OFF PUMP CORONARY SURGERY; PRIORITY JOURNAL; REVIEW; SUCTION; SURGICAL WOUND; THORACOTOMY; THROMBIN TIME; THROMBOCYTE ACTIVATION;

ANIMALS; CARDIOPULMONARY BYPASS; FIBRINOLYSIS; HEMOSTASIS; HEMOSTATICS; HUMANS; KALLIKREIN-KININ SYSTEM; PLATELET ACTIVATION; THROMBIN;

EID: 82255179277     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e3182354b7e     Document Type: Review

References (204)

1. Nomura S, Ozaki Y, Ikeda Y. Function and role of microparticles in various clinical settings. Thromb Res 2008;123:8-23
2. Roberts HR, Hoffman M, Monroe DM. A cell-based model of thrombin generation. Semin Thromb Hemost 2006;32:32-8
3. Boisclair MD, Lane DA, Philippou H, Sheikh S, Hunt B. Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin fragment F1+2. Thromb Haemost 1993;70:253-8 (Pubitemid 23222479)
4. Boisclair MD, Lane DA, Philippou H, Esnouf MP, Sheifh S, Hunt B, Smith KJ. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 1993;82:3350-7 (Pubitemid 23356706)
5. Slaughter TF, LeBleu TH, Douglas JM, Leslie JB, Parker JK, Greenberg CS. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology 1994;80:520-6 (Pubitemid 24097682)
6. Philippou H, Adami A, Boisclair MD, Lane DA. An ELISA for factor X activation peptide: application to the investigation of thrombogenesis in cardiopulmonary bypass. Br J Haematol 1995;90:432-7
7. Chandler WL, Velan T. Estimating the rate of thrombin and fibrin generation in vivo during cardiopulmonary bypass. Blood 2003;101:4355-62 (Pubitemid 36857799)
8. Bauer KA, Goodman TL, Kass BL, Rosenberg RD. Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency. J Clin Invest 1985;76: 826-36 (Pubitemid 15023141)
9. Shifman M, Pizzo S. The in vivo metabolism of antithrombin III and antithrombin III complexes. J Biol Chem 1982;257: 3243-8 (Pubitemid 12118098)
10. Leonard B, Bies R, Carlson T, Reeve EB. Further studies of the turnover of dog antithrombin III: study of 131I-labelled antithrombin protease complexes. Thromb Res 1983;30: 165-77 (Pubitemid 13079243)
11. Knudsen L, Hasenkam JM, Kure HH, Hughes P, Bellaiche L, Ahlburg P, Djurhuus C. Monitoring thrombin generation with prothrombin fragment 1.2 assay during cardiopulmonary bypass surgery. Thromb Res 1996;84:45-54 (Pubitemid 26325272)
12. Eisses MJ, Velan T, Aldea GS, Chandler WL. Strategies to reduce hemostatic activation during cardiopulmonary bypass. Thromb Res 2006;117:689-703
13. Hampton WW, Townsend MC, Schirmer WJ, Haybron DM, Fry DE. Effective hepatic blood flow during cardiopulmonary bypass. Arch Surg 1989;124:458-9 (Pubitemid 19106437)
14. Hunt BJ, Parratt RN, Segal HC, Sheikh S, Kallis P, Yacoub M. Activation of coagulation and fibrinolysis during cardiothoracic operations. Ann Thorac Surg 1998;65:712-8 (Pubitemid 28162467)
15. Valen G, Eriksson E, Risberg B, Vaage J. Fibrinolysis during cardiac surgery: release of tissue plasminogen activator in arterial and coronary sinus blood. Eur J Cardiothorac Surg 1994;8:324-30
16. Harker LA, Malpass TW, Branson HE, Hessel EA II, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980;56:824-34 (Pubitemid 11242975)
17. Pickering NJ, Brody JI, Fink GB, Finnegan JO, Ablaza S. The behavior of antithrombin III, alpha 2 macroglobulin, and alpha 1 antitrypsin during cardiopulmonary bypass. Am J Clin Pathol 1983;80:459-64 (Pubitemid 13022723)
18. Gelb AB, Roth RI, Levin J, London MJ, Noall RA, Hauck WW, Cloutier M, Verrier E, Mangano DT. Changes in blood coagulation during and following cardiopulmonary bypass: lack of correlation with clinical bleeding. Am J Clin Pathol 1996;106:87-99 (Pubitemid 26239327)
19. Mammen EF, Koets MH, Washington BC, Wolk LW, Brown JM, Burdick M, Selik NR, Wilson RF. Hemostasis changes during cardiopulmonary bypass surgery. Semin Thromb Hemost 1985;11:281-92 (Pubitemid 15225782)
20. Welters I, Menges T, Ballesteros M, Knothe C, Ruwoldt R, Gorlach G, Hempelmann G. Thrombin generation and activation of the thrombomodulin protein C system in open heart surgery depend on the underlying cardiac disease. Thromb Res 1998;92:1-9 (Pubitemid 28475325)
21. Chandler WL, Patel MA, Gravelle L, Soltow LO, Lewis K, Bishop PD, Spiess BD. Factor XIIIA and clot strength after cardiopulmonary bypass. Blood Coagul Fibrinolysis 2001;12: 101-8 (Pubitemid 32234817)
22. Davidson SJ, Burman JF, Philips SM, Onis SJ, Kelleher AA, De Souza AC, Pepper JR. Correlation between thrombin potential and bleeding after cardiac surgery in adults. Blood Coagul Fibrinolysis 2003;14:175-9 (Pubitemid 36332480)
23. Chandler WL. Effects of hemodilution, blood loss, and consumption on hemostatic factor levels during cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2005;19:459-67 (Pubitemid 41112182)
24. Moor E, Hamsten A, Blomback M, Herzfeld I, Wiman B, Ryden L. Haemostatic factors and inhibitors and coronary artery bypass grafting: preoperative alterations and relations to graft occlusion. Thromb Haemost 1994;72:335-42 (Pubitemid 24280768)
25. Yavari M, Becker RC. Coagulation and fibrinolytic protein kinetics in cardiopulmonary bypass. J Thromb Thrombolysis 2009;27:95-104
26. Van den Goor JM, Nieuwland R, Rutten PM, Tijssen JG, Hau C, Sturk A, Eijsman L, de Mol BA. Retransfusion of pericardial blood does not trigger systemic coagulation during cardiopulmonary bypass. Eur J Cardiothorac Surg 2007;31: 1029-36 (Pubitemid 46719962)
27. Velan T, Chandler WL. Effects of surgical trauma and cardiopulmonary bypass on active thrombin concentrations and the rate of thrombin inhibition in vivo. Pathophysiol Haemost Thromb 2004;33:144-56 (Pubitemid 38698115)
28. Kalweit G, Bach J, Huwer H, Winning J, Hellstern P. The impact of cardiac ischemia and reperfusion on markers of activated haemostasis and fibrinolysis during cardiopulmonary bypass: comparison of plasma levels in arterial and coronary venous blood. Thromb Res 2005;116:33-9 (Pubitemid 40546323)
29. Teufelsbauer H, Proidl S, Havel M, Vukovich T. Early activation of hemostasis during cardiopulmonary bypass: evidence for thrombin mediated hyperfibrinolysis. Thromb Haemost 1992;68:250-2
30. Marx G, Pokar H, Reuter H, Doering V, Tilsner V. The effects of aprotinin on hemostatic function during cardiac surgery. J Cardiothorac Vasc Anesth 1991;5:467-74
31. Raivio P, Kuitunen A, Suojaranta-Ylinen R, Lassila R, Petaja J. Thrombin generation during reperfusion after coronary artery bypass surgery associates with postoperative myocardial damage. J Thromb Haemost 2006;4:1523-9
32. De Haan J, Boonstra PW, Tabuchi N, van Oeveren W, Ebels T. Retransfusion of thoracic wound blood during heart surgery obscures biocompatibility of the extracorporeal circuit. J Thorac Cardiovasc Surg 1996;111:272-5 (Pubitemid 26035198)
33. De Haan J, Boonstra PW, Monnink SH, Ebels T, van Oeveren W. Retransfusion of suctioned blood during cardiopulmonary bypass impairs hemostasis. Ann Thorac Surg 1995;59:901-7
34. De Somer F, Van Belleghem Y, Caes F, Francois K, Van Overbeke H, Arnout J, Taeymans Y, Van Nooten G. Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2002;123: 951-8
35. Eisses MJ, Seidel K, Aldea GS, Chandler WL. Reducing hemostatic activation during cardiopulmonary bypass: acombined approach. Anesth Analg 2004;98:1208-16 (Pubitemid 38525568)
36. Raivio P, Lassila R, Petaja J. Thrombin in myocardial ischemiareperfusion during cardiac surgery. Ann Thorac Surg 2009;88: 318-25
37. Hemker HC, Beguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 1995;74:134-8
38. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Beguin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003;33:4-15 (Pubitemid 37449290)
39. Coakley M, Hall JE, Evans C, Duff E, Billing V, Yang L, McPherson D, Stephens E, Macartney N, Wilkes AR, Collins PW. Assessment of thrombin generation measured before and after cardiopulmonary bypass surgery and its association with post-operative bleeding. J Thromb Haemost 2010;9: 282-92
40. Eichinger S, Hron G, Kollars M, Kyrle PA. Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer. Clin Chem 2008;54:2042-8 (Pubitemid 352774038)
41. Campbell DJ. The kallikrein-kinin system in humans. Clin Exp Pharmacol Physiol 2001;28:1060-5 (Pubitemid 34053524)
42. Sharma JN. Role of tissue kallikrein-kininogen-kinin pathways in the cardiovascular system. Arch Med Res 2006;37: 299-306
43. Sharma JN. Involvement of the kinin-forming system in the physiopathology of rheumatoid inflammation. Agents Actions Suppl 1992;38:343-61
44. Schmaier AH, McCrae KR. The plasma kallikrein-kinin system: its evolution from contact activation. J Thromb Haemost 2007;5:2323-9 (Pubitemid 350154338)
45. Fuhrer G, Gallimore MJ, Heller W, Hoffmeister HE. Studies on components of the plasma kallikrein-kinin system in patients undergoing cardiopulmonary bypass. Adv Exp Med Biol 1986;198:385-91
46. Campbell DJ, Dixon B, Kladis A, Kemme M, Santamaria JD. Activation of the kallikrein-kinin system by cardiopulmonary bypass in humans. Am J Physiol Regul Integr Comp Physiol 2001;281:R1059-70
47. Gallimore MJ, Jones DW, Winter M, Wendel HP. Changes in high molecular weight kininogen levels during and after cardiopulmonary bypass surgery measured using a chromogenic peptide substrate assay. Blood Coagul Fibrinolysis 2002;13:561-8
48. Cugno M, Nussberger J, Biglioli P, Alamanni F, Coppola R, Agostoni A. Increase of bradykinin in plasma of patients undergoing cardiopulmonary bypass: the importance of lung exclusion. Chest 2001;120:1776-82 (Pubitemid 34053433)
49. Brown NJ, Gainer JV, Stein CM, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension 1999;33:1431-5 (Pubitemid 29282666)
50. Brown NJ, Nadeau JH, Vaughan DE. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost 1997;77:522-5 (Pubitemid 27121020)
51. Agostoni A, Cugno M. Influence of contact system deficiencies during cardiopulmonary bypass. Thromb Haemost 2001;85: 191-2 (Pubitemid 32140557)
52. Stavrou E, Schmaier AH. Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis? Thromb Res 2010;125:210-5
53. Burman J, Chung H, Lane D, Philippou H, Adami A, Lincoln J. Role of factor XII in thrombin generation and fibrinolysis during cardiopulmonary bypass. Lancet 1994;344:1192-3 (Pubitemid 24323709)
54. Chung HI, Burman JF, Balogun BA, Lincoln JCR, Pepper JR. Elevated fibrinolysis in cardiopulmonary bypass is factor XII dependent. Fibrinolysis 1994;8:84-5 (Pubitemid 24290751)
55. Braat EA, Dooijewaard G, Rijken DC. Fibrinolytic properties of activated FXII. Eur J Biochem 1999;263:904-11 (Pubitemid 29361966)
56. Zhao X, Courtney JM, Yin HQ, West RH, Lowe GD. Blood interactions with plasticised poly (vinyl chloride): influence of surface modification. J Mater Sci Mater Med 2008;19:713-9 (Pubitemid 351236765)
57. Chandler WL, Velan T. Secretion of tissue plasminogen activator and plasminogen activator inhibitor 1 during cardiopulmonary bypass. Thromb Res 2003;112:185-92
58. Tanaka K, Takao M, Yada I, Yuasa H, Kusagawa M, Deguchi K. Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery. J Cardiothorac Anesth 1989;3:181-8 (Pubitemid 19098790)
59. Chandler WL, Fitch JCK, Wall MH, Verrier ED, Cochran RP, Soltow LO, Spiess BD. Individual variations in the fibrinolytic response during and after cardiopulmonary bypass. Thromb Haemost 1995;74:1293-7
60. Booyse FM, Bruce R, Dolenak D, Grover M, Casey LC. Rapid release and deactivation of plasminogen activators in human endothelial cell cultures in the presence of thrombin and ionophore A23187. Semin Thromb Hemost 1986;12:228-30 (Pubitemid 17198759)
61. Pretorius M, Scholl FG, McFarlane JA, Murphey LJ, Brown NJ. A pilot study indicating that bradykinin B2 receptor antagonism attenuates protamine-related hypotension after cardiopulmonary bypass. Clin Pharmacol Ther 2005;78: 477-85 (Pubitemid 41698902)
62. Fuhrer G, Gallimore MJ, Heller W, Hoffmeister HE. Aprotinin in cardiopulmonary bypass: effects on the Hageman factor (FXII)- kallikrein system and blood loss. Blood Coagul Fibrinolysis 1992;3:99-104
63. Chandler WL, Alessi MC, Aillaud MF, Vague P, Juhan-Vague I. Formation, inhibition and clearance of plasmin in vivo. Haemostasis 2000;30:204-18 (Pubitemid 32046014)
64. van den Goor JM, van Oeveren W, Rutten PM, Tijssen JG, Eijsman L. Adhesion of thrombotic components to the surface of a clinically used oxygenator is not affected by trillium coating. Perfusion 2006;21:165-72 (Pubitemid 43933313)
65. Nishida H, Aomi S, Tomizawa Y, Endo M, Koyanagi H, Nojiri C, Oshiyama H, Kido T, Yokoyama K. Comparative study of biocompatibility between the open circuit and closed circuit in cardiopulmonary bypass. Artif Organs 1999;23:547-51 (Pubitemid 29293467)
66. Chandler WL, Velan T. Plasmin generation and D-dimer formation during cardiopulmonary bypass. Blood Coagul Fibrinolysis 2004;15:583-91 (Pubitemid 39372475)
67. de Haan J, van Oeveren W. Platelets and soluble fibrin promote plasminogen activation causing downregulation of platelet glycoprotein Ib/IX complexes: protection by aprotinin. Thromb Res 1998;92:171-9 (Pubitemid 28541063)
68. Michelson AD, Barnard MR. Plasmin-induced redistribution of platelet glycoprotein Ib. Blood 1990;76:2005-10
69. Rinder CS, Bohnert J, Rinder HM, Mitchell J, Ault K, Hillman R. Platelet activation and aggregation during cardiopulmonary bypass. Anesthesiology 1991;75:388-93
70. Slaughter TF, Sreeram G, Sharma AD, El-Moalem H, East CJ, Greenberg CS. Reversible shear-mediated platelet dysfunction during cardiac surgery as assessed by the PFA-100 platelet function analyzer. Blood Coagul Fibrinolysis 2001;12: 85-93 (Pubitemid 32234815)
71. Velik-Salchner C, Maier S, Innerhofer P, Kolbitsch C, Streif W, Mittermayr M, Praxmarer M, Fries D. An assessment of cardiopulmonary bypass-induced changes in platelet function using whole blood and classical light transmission aggregometry: the results of a pilot study. Anesth Analg 2009;108:1747-54
72. Ray MJ, Marsh NA, Hawson GAT. Relationship of fibrinolysis and platelet function to bleeding after cardiopulmonary bypass. Blood Coagul Fibrinolysis 1994;5:679-85 (Pubitemid 24366359)
73. Freyburger G, Janvier G, Dief S, Boisseau MR. Fibrinolytic and hemorheologic alterations during and after elective aortic graft surgery: implications for postoperative management. Anesth Analg 1993;76:504-12 (Pubitemid 23077105)
74. Lu H, Du Buit C, Soria J, Touchot B, Chollet B, Commin PL, Conseiller C, Echter E, Soria C. Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with and without aprotinin therapy. Thromb Haemost 1994;72: 438-43 (Pubitemid 24280787)
75. Rifon J, Paramo JA, Panizo C, Montes R, Rocha E. The increase of plasminogen activator inhibitor activity is associated with graft occlusion in patients undergoing aortocoronary bypass surgery. Br J Haematol 1997;99:262-7 (Pubitemid 27497549)
76. Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 2003;75:S715-20 (Pubitemid 36184553)
77. Warren OJ, Smith AJ, Alexiou C, Rogers PL, Jawad N, Vincent C, Darzi AW, Athanasiou T. The inflammatory response to cardiopulmonary bypass. Part 1. Mechanisms of pathogenesis. J Cardiothorac Vasc Anesth 2009;23:223-31
78. Warren OJ, Watret AL, de Wit KL, Alexiou C, Vincent C, Darzi AW, Athanasiou T. The inflammatory response to cardiopulmonary bypass. Part 2. Anti-inflammatory therapeutic strategies. J Cardiothorac Vasc Anesth 2009;23:384-93
79. Levy JH. Anti-inflammatory strategies and hemostatic agents: old drugs, new ideas. Hematol Oncol Clin North Am 2007;21: 89-101 (Pubitemid 46156983)
80. Laffey JG, Boylan JF, Cheng DC. The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. Anesthesiology 2002;97:215-52 (Pubitemid 34733943)
81. Shibamiya A, Tabuchi N, Chung J, Sunamori M, Koyama T. Formation of tissue factor-bearing leukocytes during and after cardiopulmonary bypass. Thromb Haemost 2004;92: 124-31 (Pubitemid 39010875)
82. Chung J, Suzuki H, Tabuchi N, Sato K, Shibamiya A, Koyama T. Identification of tissue factor and platelet-derived particles on leukocytes during cardiopulmonary bypass by flow cytometry and immunoelectron microscopy. Thromb Haemost 2007;98:368-74 (Pubitemid 47250240)
83. Johnell M, Elgue G, Thelin S, Larsson R, Siegbahn A. Cell adhesion and tissue factor upregulation in oxygenators used during coronary artery bypass grafting are modified by the Corline Heparin Surface. Scand Cardiovasc J 2002;36:351-7 (Pubitemid 36138682)
84. Barstad RM, Ovrum E, Ringdal MA, Oystese R, Hamers MJ, Veiby OP, Rolfsen T, Stephens RW, Sakariassen KS. Induction of monocyte tissue factor procoagulant activity during coronary artery bypass surgery is reduced with heparin-coated extracorporeal circuit. Br J Haematol 1996;94:517-25 (Pubitemid 26284078)
85. Tabuchi N, Shibamiya A, Koyama T, Fukuda T, van Oeveren W, Sunamori M. Activated leukocytes adsorbed on the surface of an extracorporeal circuit. Artif Organs 2003;27:591-4 (Pubitemid 36683663)
86. el Habbal MH, Carter H, Smith LJ, Elliott MJ, Strobel S. Neutrophil activation in paediatric extracorporeal circuits: effect of circulation and temperature variation. Cardiovasc Res 1995;29:102-7
87. Gillinov AM, Bator JM, Zehr KJ, Redmond JM, Burch RM, Ko C, Winkelstein JA, Stuart RS, Baumgartner WA, Cameron DE. Neutrophil adhesion molecule expression during cardiopulmonary bypass with bubble and membrane oxygenators. Ann Thorac Surg 1993;56:847-53 (Pubitemid 23316062)
88. Shen M, Horbett TA. The effects of surface chemistry and adsorbed proteins on monocyte/macrophage adhesion to chemically modified polystyrene surfaces. J Biomed Mater Res 2001;57:336-45 (Pubitemid 32885265)
89. Parratt R, Hunt BJ. Direct activation of factor X by monocytes occurs during cardiopulmonary bypass. Br J Haematol 1998;101:40-6 (Pubitemid 28197772)
90. Hattori T, Khan MM, Colman RW, Edmunds LH Jr. Plasma tissue factor plus activated peripheral mononuclear cells activate factors VII and X in cardiac surgical wounds. J Am Coll Cardiol 2005;46:707-13 (Pubitemid 41132702)
91. Sturk-Maquelin KN, Nieuwland R, Romijn FP, Eijsman L, Hack CE, Sturk A. Pro- and non-coagulant forms of non-cellbound tissue factor in vivo. J Thromb Haemost 2003;1:1920-6
92. Philippou H, Adami A, Davidson SJ, Pepper JR, Burman JF, Lane DA. Tissue factor is rapidly elevated in plasma collected from the pericardial cavity during cardiopulmonary bypass. Thromb Haemost 2000;84:124-8 (Pubitemid 30433680)
93. Weiler H. Regulation of inflammation by the protein C system. Crit Care Med 2010;38:S18-25
94. Danese S, Vetrano S, Zhang L, Poplis VA, Castellino FJ. The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood 2010;115: 1121-30
95. Musial J, Niewiarowski S, Rucinski B, Stewart GJ, Cook JJ, Williams JA, Edmunds LH Jr. Inhibition of platelet adhesion to surfaces of extracorporeal circuits by disintegrins: RGDcontaining peptides from viper venoms. Circulation 1990;82: 261-73 (Pubitemid 20216337)
96. Tsai WB, Grunkemeier JM, McFarland CD, Horbett TA. Platelet adhesion to polystyrene-based surfaces preadsorbed with plasmas selectively depleted in fibrinogen, fibronectin, vitronectin, or von Willebrands factor. J Biomed Mater Res 2002;60:348-59 (Pubitemid 34296803)
97. Niimi Y, Ichinose F, Ishiguro Y, Terui K, Uezono S, Morita S, Yamane S. The effects of heparin coating of oxygenator fibers on platelet adhesion and protein adsorption. Anesth Analg 1999;89:573-9 (Pubitemid 29409799)
98. Gorbet MB, Sefton MV. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials 2004;25:5681-703 (Pubitemid 38624449)
99. Gemmell CH, Ramirez SM, Yeo EL, Sefton MV. Platelet activation in whole blood by artificial surfaces: identification of platelet-derived microparticles and activated platelet binding to leukocytes as material-induced activation events. J Lab Clin Med 1995;125:276-87
100. Grunkemeier JM, Tsai WB, Horbett TA. Hemocompatibility of treated polystyrene substrates: contact activation, platelet adhesion, and procoagulant activity of adherent platelets. J Biomed Mater Res 1998;41:657-70 (Pubitemid 28355451)
101. Gemmell CH. Assessment of material-induced procoagulant activity by a modified Russell viper venom coagulation time test. J Biomed Mater Res 1998;42:611-6 (Pubitemid 28503767)
102. Zillmann A, Luther T, Muller I, Kotzsch M, Spannagl M, Kauke T, Oelschlagel U, Zahler S, Engelmann B. Plateletassociated tissue factor contributes to the collagen-triggered activation of blood coagulation. Biochem Biophys Res Commun 2001;281:603-9 (Pubitemid 32928197)
103. Khuri S, Wolfe J, Josa M, Axford TC, Szymanski I, Assousa S, Ragno G, Patel M, Silverman A, Park M, Valeri CR. Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss. J Thorac Cardiovasc Surg 1992;104:94-107
104. Shigeta O, Kojima H, Jikuya T, Terada Y, Atsumi N, Sakakibara Y, Nagasawa T, Mitsui T. Aprotinin inhibits plasmininduced platelet activation during cardiopulmonary bypass. Circulation 1997;96:569-74 (Pubitemid 27329435)
105. Diago MC, Garcia-Unzueta MT, Marcano G, Merino J, Salas E, Amado JA. Serum soluble selectins in patients undergoing cardiopulmonary bypass: relationship with circulating blood cells and inflammation-related cytokines. Acta Anaesthesiol Scand 1997;41:725-30 (Pubitemid 27297879)
106. Vallely MP, Bannon PG, Bayfield MS, Hughes CF, Kritharides L. Quantitative and temporal differences in coagulation, fibrinolysis and platelet activation after on-pump and offpump coronary artery bypass surgery. Heart Lung Circ 2009;18:123-30
107. Lo B, Fijnheer R, Castigliego D, Borst C, Kalkman CJ, Nierich AP. Activation of hemostasis after coronary artery bypass grafting with or without cardiopulmonary bypass. Anesth Analg 2004;99:634-40 (Pubitemid 39100345)
108. Johnell M, Elgue G, Larsson R, Larsson A, Thelin S, Siegbahn A. Coagulation, fibrinolysis, and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface. J Thorac Cardiovasc Surg 2002;124:321-32 (Pubitemid 35025609)
109. Kongsgaard UE, Hovig T, Brosstad F, Geiran O. Platelets in shed mediastinal blood used for postoperative autotransfusion. Acta Anaesthesiol Scand 1993;37:265-8 (Pubitemid 23199798)
110. Fabre O, Vincentelli A, Corseaux D, Juthier F, Susen S, Bauters A, Van Belle E, Mouquet F, Le Tourneau T, Decoene C, Crepin F, Prat A, Jude B. Comparison of blood activation in the wound, active vent, and cardiopulmonary bypass circuit. Ann Thorac Surg 2008;86:537-41 (Pubitemid 351978012)
111. Koster A, Bottcher W, Merkel F, Hetzer R, Kuppe H. The more closed the bypass system the better: a pilot study on the effects of reduction of cardiotomy suction and passive venting on hemostatic activation during on-pump coronary artery bypass grafting. Perfusion 2005;20:285-8 (Pubitemid 41448462)
112. Skrabal CA, Khosravi A, Choi YH, Kaminski A, Westphal B, Steinhoff G, Liebold A. Pericardial suction blood separation attenuates inflammatory response and hemolysis after cardiopulmonary bypass. Scand Cardiovasc J 2006;40:219-23
113. Takayama H, Soltow LO, Chandler WL, Vocelka CR, Aldea GS. Does the type of surgery effect systemic response following cardiopulmonary bypass? J Card Surg 2007;22:307-13 (Pubitemid 47174331)
114. Ferraris VA, Ferraris SP, Singh A, Fuhr W, Koppel D, McKenna D, Rodriguez E, Reich H. The platelet thrombin receptor and postoperative bleeding. Ann Thorac Surg 1998;65:352-8 (Pubitemid 28083327)
115. Day JR, Punjabi PP, Randi AM, Haskard DO, Landis RC, Taylor KM. Clinical inhibition of the seven-transmembrane thrombin receptor (PAR1) by intravenous aprotinin during cardiothoracic surgery. Circulation 2004;110:2597-600 (Pubitemid 39453008)
116. Niewiarowski S, Senyi AF, Gillies P. Plasmin-induced platelet aggregation and platelet release reaction: effects on hemostasis. J Clin Invest 1973;52:1647-59
117. de Haan J, Schonberger J, Haan J, van Oeveren W, Eijgelaar A. Tissue-type plasminogen activator and fibrin monomers synergistically cause platelet dysfunction during retransfusion of shed blood after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993;106:1017-23 (Pubitemid 24018543)
118. Mao Y, Jin J, Daniel JL, Kunapuli SP. Regulation of plasmininduced protease-activated receptor 4 activation in platelets. Platelets 2009;20:191-8
119. Quinton TM, Kim S, Derian CK, Jin J, Kunapuli SP. Plasminmediated activation of platelets occurs by cleavage of protease-activated receptor 4. J Biol Chem 2004;279:18434-9 (Pubitemid 38623260)
120. van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CR. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990;99:788-96
121. Huang H, Ding W, Su Z, Zhang W. Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery. J Thorac Cardiovasc Surg 1993;106:11-8 (Pubitemid 23216042)
122. Soslau G, Horrow J, Brodsky I. Effect of tranexamic acid on platelet ADP during extracorporeal circulation. Am J Hematol 1991;38:113-9
123. Khan MM, Hattori T, Niewiarowski S, Edmunds LH Jr, Colman RW. Truncated and microparticle-free soluble tissue factor bound to peripheral monocytes preferentially activate factor VII. Thromb Haemost 2006;95:462-8
124. Weerwind PW, Lindhout T, Caberg NE, De Jong DS. Thrombin generation during cardiopulmonary bypass: the possible role of retransfusion of blood aspirated from the surgical field. Thromb J 2003;1:3
125. Chung JH, Gikakis N, Rao AK, Drake TA, Colman RW, Edmunds LH. Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. Circulation 1996;93:2014-8 (Pubitemid 26165564)
126. Aldea GS, Soltow LO, Chandler WL, Triggs CM, Vocelka CR, Crockett GI, Shin YT, Curtis WE, Verrier ED. Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits. J Thorac Cardiovasc Surg 2002;123:742-55 (Pubitemid 34535085)
127. Westerberg M, Bengtsson A, Jeppsson A. Coronary surgery without cardiotomy suction and autotransfusion reduces the postoperative systemic inflammatory response. Ann Thorac Surg 2004;78:54-9 (Pubitemid 38833898)
128. Nakahira A, Sasaki Y, Hirai H, Matsuo M, Morisaki A, Suehiro S, Shibata T. Cardiotomy suction, but not open venous reservoirs, activates coagulofibrinolysis in coronary artery surgery. J Thorac Cardiovasc Surg 2011;141:1289-97
129. Wang G, Bainbridge D, Martin J, Cheng D. The efficacy of an intraoperative cell saver during cardiac surgery: a meta-analysis of randomized trials. Anesth Analg 2009;109: 320-30
130. Belway D, Rubens FD. Currently available biomaterials for use in cardiopulmonary bypass. Expert Rev Med Devices 2006;3:345-55
131. Ranucci M, Mazzucco A, Pessotto R, Grillone G, Casati V, Porreca L, Maugeri R, Meli M, Magagna P, Cirri S, Giomarelli P, Lorusso R, de Jong A. Heparin-coated circuits for high-riskpatients: a multicenter, prospective, randomized trial. Ann Thorac Surg 1999;67:994-1000 (Pubitemid 29238286)
132. Mangoush O, Purkayastha S, Haj-Yahia S, Kinross J, Hayward M, Bartolozzi F, Darzi A, Athanasiou T. Heparin-bonded circuits versus nonheparin-bonded circuits: an evaluation of their effect on clinical outcomes. Eur J Cardiothorac Surg 2007;31:1058-69 (Pubitemid 46729655)
133. Gunaydin S. Emerging technologies in biocompatible surface modifying additives: quest for physiologic cardiopulmonary bypass. Curr Med Chem Cardiovasc Hematol Agents 2004;2: 295-302 (Pubitemid 39200174)
134. De Somer F, Francois K, van Oeveren W, Poelaert J, De Wolf D, Ebels T, Van Nooten G. Phosphorylcholine coating of extracorporeal circuits provides natural protection against blood activation by the material surface. Eur J Cardiothorac Surg 2000;18:602-6
135. Ereth MH, Nuttall GA. Biocompatibility of Trillium Biopassive Surface-coated oxygenator versus uncoated oxygenator during cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2001;15:545-50
136. Pappalardo F, Della Valle P, Crescenzi G, Corno C, Franco A, Torracca L, Alfieri O, Galli L, Zangrillo A, DAngelo A. Phosphorylcholine coating may limit thrombin formation during high-risk cardiac surgery: a randomized controlled trial. Ann Thorac Surg 2006;81:886-91 (Pubitemid 43247655)
137. Zimmermann AK, Weber N, Aebert H, Ziemer G, Wendel HP. Effect of biopassive and bioactive surface-coatings on the hemocompatibility of membrane oxygenators. J Biomed Mater Res B Appl Biomater 2007;80:433-9
138. Ranucci M, Balduini A, Ditta A, Boncilli A, Brozzi S. A systematic review of biocompatible cardiopulmonary bypass circuits and clinical outcome. Ann Thorac Surg 2009;87:1311-9
139. Fromes Y, Gaillard D, Ponzio O, Chauffert M, Gerhardt MF, Deleuze P, Bical OM. Reduction of the inflammatory response following coronary bypass grafting with total minimal extracorporeal circulation. Eur J Cardiothorac Surg 2002;22:527-33 (Pubitemid 35286933)
140. Rahe-Meyer N, Solomon C, Tokuno ML, Winterhalter M, Shrestha M, Hahn A, Tanaka K. Comparative assessment of coagulation changes induced by two different types of heartlung machine. Artif Organs 2010;34:3-12
141. Biancari F, Rimpilainen R. Meta-analysis of randomised trials comparing the effectiveness of miniaturised versus conventional cardiopulmonary bypass in adult cardiac surgery. Heart 2009;95:964-9
142. Zangrillo A, Garozzo FA, Biondi-Zoccai G, Pappalardo F, Monaco F, Crivellari M, Bignami E, Nuzzi M, Landoni G. Miniaturized cardiopulmonary bypass improves short-term outcome in cardiac surgery: a meta-analysis of randomized controlled studies. J Thorac Cardiovasc Surg 2010;139:1162-9
143. Halkos ME, Puskas JD. Off-pump coronary surgery: where do we stand in 2010? Curr Opin Cardiol 2010;25:583-8
144. Casati V, Gerli C, Franco A, Della Valle P, Benussi S, Alfieri O, Torri G, DAngelo A. Activation of coagulation and fibrinolysis during coronary surgery: on-pump versus off-pump techniques. Anesthesiology 2001;95:1103-9 (Pubitemid 33043224)
145. Untch BR, Jeske WP, Schwartz J, Botkin S, Prechel M, Walenga JM, Bakhos M. Inflammatory and hemostatic activation in patients undergoing off-pump
146. Ballotta A, Saleh HZ, El Baghdady HW, Gomaa M, Belloli F, Kandil H, Balbaa Y, Bettini F, Bossone E, Menicanti L, Frigiola A, Bellucci C, Mehta RH. Comparison of early platelet activation in patients undergoing on-pump versus off-pump coronary artery bypass surgery. J Thorac Cardiovasc Surg 2007;134:132-8 (Pubitemid 46962015)
147. Puskas JD, Williams WH, Mahoney EM, Huber PR, Block PC, Duke PG, Staples JR, Glas KE, Marshall JJ, Leimbach ME, McCall SA, Petersen RJ, Bailey DE, Weintraub WS, Guyton RA. Off-pump vs conventional coronary artery bypass grafting: early and 1-year graft patency, cost, and quality-of-life outcomes-a randomized trial. JAMA 2004;291:1841-9 (Pubitemid 38509496)
148. Garvin S, Fitzgerald D, Muehlschlegel JD, Perry TE, Fox AA, Shernan SK, Collard CD, Aranki S, Body SC. Heparin dose response is independent of preoperative antithrombin activity in patients undergoing coronary artery bypass graft surgery using low heparin concentrations. Anesth Analg 2010;111:856-61
149. Hirsh J. Current anticoagulant therapy: unmet clinical needs. Thromb Res 2003;109:S1-8 (Pubitemid 36724831)
150. Lobato RL, Despotis GJ, Levy JH, Shore-Lesserson LJ, Carlson MO, Bennett-Guerrero E. Anticoagulation management during cardiopulmonary bypass: a survey of 54 North American institutions. J Thorac Cardiovasc Surg 2010;139:1665-6
151. Fitzgerald DJ, Patel A, Body SC, Garvin S. The relationship between heparin level and activated clotting time in the adult cardiac surgery population. Perfusion 2009;24:93-6
152. Brister SJ, Ofosu FA, Buchanan MR. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant? Thromb Haemost 1993;70:259-62 (Pubitemid 23222480)
153. Koster A, Fischer T, Praus M, Haberzettl H, Kuebler WM, Hetzer R, Kuppe H. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management. Anesthesiology 2002;97:837-41
154. Despotis GJ, Joist JH, Hogue CWJ, Alsoufiev A, Kater K, Goodnough LT, Santoro SA, Spitznagel E, Rosenblum M, Lappas DG. The impact of heparin concentration and activated clotting time monitoring on blood conservation: a prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1995;110:46-54
155. Slight RD, Buell R, Nzewi OC, McClelland DB, Mankad PS. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2008;22:47-52 (Pubitemid 351187885)
156. Khuri SF, Valeri CR, Loscalzo J, Weinstein MJ, Birjiniuk V, Healey NA, MacGregor H, Doursounian M, Zolkewitz MA. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg 1995;60: 1008-14
157. Kemme MJ, Burggraaf J, Schoemaker RC, Kluft C, Cohen AF. Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. Br J Clin Pharmacol 2002;54:627-34 (Pubitemid 36002591)
158. Sandset PM, Bendz B, Hansen JB. Physiological function of tissue factor pathway inhibitor and interaction with heparins. Haemostasis 2000;30:48-56 (Pubitemid 32234139)
159. Levy JH, Tanaka KA, Hursting MJ. Reducing thrombotic complications in the perioperative setting: an update on heparin-induced thrombocytopenia. Anesth Analg 2007;105: 570-82 (Pubitemid 47300828)
160. Levy JH, Winkler AM. Heparin-induced thrombocytopenia and cardiac surgery. Curr Opin Anaesthesiol 2010;23:74-9
161. Sniecinski RM, Hursting MJ, Paidas MJ, Levy JH. Etiology and assessment of hypercoagulability with lessons from heparin-induced thrombocytopenia. Anesth Analg 2011;112: 46-58
162. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003;76:2121-31
163. Gluckman TJ, Segal JB, Schulman SP, Shapiro EP, Kickler TS, Prechel MM, Conte JV, Walenga JM, Shafique I, Rade JJ, Menicanti L, Frigiola A. Effect of anti-platelet factor- 4/heparin antibody induction on early saphenous vein graft occlusion after coronary artery bypass surgery. J Thromb Haemost 2009;7:1457-64
164. Van De Car DA, Rao SV, Ohman EM. Bivalirudin: a review of the pharmacology and clinical application. Expert Rev Cardiovasc Ther 2010;8:1673-81
165. Koster A, Yeter R, Buz S, Kuppe H, Hetzer R, Lincoff AM, Dyke CM, Smedira NG, Spiess B, Menicanti L, Frigiola A. Assessment of hemostatic activation during cardiopulmonary bypass for coronary artery bypass grafting with bivalirudin: results of a pilot study. J Thorac Cardiovasc Surg 2005;129: 1391-4 (Pubitemid 40804860)
166. Smedira NG, Dyke CM, Koster A, Jurmann M, Bhatia DS, Hu T, McCarthy HL II, Lincoff AM, Spiess BD, Aronson S. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg 2006;131:686-92
167. Dyke CM, Smedira NG, Koster A, Aronson S, McCarthy HL II, Kirshner R, Lincoff AM, Spiess BD. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg 2006;131:533-9
168. Martin ME, Kloecker GH, Laber DA. Argatroban for anticoagulation during cardiac surgery. Eur J Haematol 2007;78:161-6 (Pubitemid 46061392)
169. Smith AI, Stroud R, Damiani P, Vaynblat M. Use of argatroban for anticoagulation during cardiopulmonary bypass in a patient with heparin allergy. Eur J Cardiothorac Surg 2008;34:1113-4
170. Follis F, Filippone G, Montalbano G, Floriano M, Lobianco E, DAncona G, Follis M. Argatroban as a substitute of heparin during cardiopulmonary bypass: a safe alternative? Interact Cardiovasc Thorac Surg 2010;10:592-6
171. Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011;123:1436-50
172. Zaidan JR, Johnson S, Brynes R, Monroe S, Guffin AV. Rate of protamine administration: its effect on heparin reversal and antithrombin recovery after coronary artery surgery. Anesth Analg 1986;65:377-80 (Pubitemid 16162566)
173. Ranucci M, Ditta A, Boncilli A, Cotza M, Carboni G, Brozzi S, Bonifazi C, Tiezzi A. Determinants of antithrombin consumption in cardiac operations requiring cardiopulmonary bypass. Perfusion 2004;19:47-52 (Pubitemid 38386649)
174. Okita Y, Takamoto S, Ando M, Morota T, Yamaki F, Matsukawa R, Kawashima Y. Coagulation and fibrinolytic system in aortic surgery under deep hypothermic circulatory arrest with aprotinin: importance of adequate heparinization. Circulation 1997;96:II-376-81
175. Slaughter TF, Mark JB, El-Moalem H, Hayward KA, Hilton AK, Hodgins LP, Greenberg CS. Hemostatic effects of antithrombin III supplementation during cardiac surgery: results of a prospective randomized investigation. Blood Coagul Fibrinolysis 2001;12:25-31 (Pubitemid 32150248)
176. Sniecinski R, Szlam F, Chen EP, Bader SO, Levy JH, Tanaka KA. Antithrombin deficiency increases thrombin activity after prolonged cardiopulmonary bypass. Anesth Analg 2008;106: 713-8 (Pubitemid 351301383)
177. Ranucci M, Frigiola A, Menicanti L, Ditta A, Boncilli A, Brozzi S. Postoperative antithrombin levels and outcome in cardiac operations. Crit Care Med 2005;33:355-60 (Pubitemid 40216549)
178. Garvin S, Muehlschlegel JD, Perry TE, Chen J, Liu KY, Fox AA, Collard CD, Aranki SF, Shernan SK, Body SC. Postoperative activity, but not preoperative activity, of antithrombin is associated with major adverse cardiac events after coronary artery bypass graft surgery. Anesth Analg 2010;111: 862-9
179. Koster A, Fischer T, Gruendel M, Mappes A, Kuebler WM, Bauer M, Kuppe H. Management of heparin resistance during cardiopulmonary bypass: the effect of five different anticoagulation strategies on hemostatic activation. J Cardiothorac Vasc Anesth 2003;17:171-5 (Pubitemid 36457470)
180. Avidan MS, Levy JH, van Aken H, Feneck RO, Latimer RD, Ott E, Martin E, Birnbaum DE, Bonfiglio LJ, Kajdasz DK, Despotis GJ. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005;130:107-13 (Pubitemid 40941676)
181. Levy JH, Despotis GJ, Szlam F, Olson P, Meeker D, Weisinger A, Menicanti L, Frigiola A. Recombinant human transgenic antithrombin in cardiac surgery: a dose-finding study. Anesthesiology 2002;96:1095-102 (Pubitemid 34462569)
182. Rossi M, Martinelli L, Storti S, Corrado M, Marra R, Varano C, Schiavello R, Menicanti L, Frigiola A. The role of antithrombin III in the perioperative management of the patient with unstable angina. Ann Thorac Surg 1999;68:2231-6 (Pubitemid 30027855)
183. Williams MR, DAmbra AB, Beck JR, Spanier TB, Morales DL, Helman DN, Oz MC. A randomized trial of antithrombin concentrate for treatment of heparin resistance. Ann Thorac Surg 2000;70:873-7
184. Avidan MS, Levy JH, Scholz J, Delphin E, Rosseel PM, Howie MB, Gratz I, Bush CR, Skubas N, Aldea GS, Licina M, Bonfiglio LJ, Kajdasz DK, Ott E, Despotis GJ. A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology 2005;102:276-84 (Pubitemid 40189074)
185. Conley JC, Plunkett PF, Menicanti L, Frigiola A. Antithrombin III in cardiac surgery: an outcome study. J Extra Corpor Technol 1998;30:178-83 (Pubitemid 29152673)
186. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007;356:2301-11 (Pubitemid 46849160)
187. Ozier Y, Bellamy L. Pharmacological agents: antifibrinolytics and desmopressin. Best Pract Res Clin Anaesthesiol 2010;24:107-19
188. Henry DA, Carless PA, Moxey AJ, OConnell D, Stokes BJ, McClelland B, Laupacis A, Fergusson D. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2007;4:CD001886
189. Brown JR, Birkmeyer NJ, OConnor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 2007;115: 2801-13 (Pubitemid 46876483)
190. Martin K, Wiesner G, Breuer T, Lange R, Tassani P. The risks of aprotinin and tranexamic acid in cardiac surgery: a oneyear follow-up of 1188 consecutive patients. Anesth Analg 2008;107:1783-90
191. Ide M, Bolliger D, Taketomi T, Tanaka KA. Lessons from the aprotinin saga: current perspective on antifibrinolytic therapy in cardiac surgery. J Anesth 2010;24:96-106
192. Kang HM, Kalnoski MH, Frederick M, Chandler WL, Menicanti L, Frigiola A. The kinetics of plasmin inhibition by aprotinin in vivo. Thromb Res 2005;115:327-40
193. Levy JH, Sypniewski E. Aprotinin: a pharmacologic overview. Orthopedics 2004;27:s653-8 (Pubitemid 38923419)
194. Segal H, Sheikh S, Kallis P, Cottam S, Beard C, Potter D, Townsend E, Bidstrup BP, Yacoub M, Hunt BJ. Complement activation during major surgery: the effect of extracorporeal circuits and high-dose aprotinin therapy. J Cardiothorac Vasc Anesth 1998;12:542-7 (Pubitemid 28473813)
195. Longstaff C. Studies on the mechanisms of action of aprotinin and tranexamic acid as plasmin inhibitors and antifibrinolytic agents. Blood Coagul Fibrinolysis 1994;5:537-42 (Pubitemid 24301574)
196. Rossi M, Storti S, Martinelli L, Varano C, Marra R, Zamparelli R, Possati G, Schiavello R. A pump-prime aprotinin dose in cardiac surgery: appraisal of its effects on the hemostatic system. J Cardiothorac Vasc Anesth 1997;11:835-9 (Pubitemid 27523086)
197. Ray MJ, Marsh NA. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin. Thromb Haemost 1997;78:1021-6 (Pubitemid 27417294)
198. Fergusson DA, Hebert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Duke PC, Arellano R, Blajchman MA, Bussieres JS, Cote D, Karski J, Martineau R, Robblee JA, Rodger M, Wells G, Clinch J, Pretorius R. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008;358:2319-31 (Pubitemid 351749156)
199. Karkouti K, Wijeysundera DN, Yau TM, McCluskey SA, Tait G, Beattie WS. The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery. Anesth Analg 2010;110:21-9
200. Perry TE, Muehlschlegel JD, Body SC. Genomics: risk and outcomes in cardiac surgery. Anesthesiol Clin 2008;26:399-417
201. Shore-Lesserson L, Reich DL. A case of severe diffuse venous thromboembolism associated with aprotinin and hypothermic circulatory arrest in a cardiac surgical patient with factor V Leiden. Anesthesiology 2006;105:219-21 (Pubitemid 44305212)
202. Podgoreanu MV, Schwinn DA. New paradigms in cardiovascular medicine: emerging technologies and practices- perioperative genomics. J Am Coll Cardiol 2005;46:1965-77 (Pubitemid 41713577)
203. Welsby IJ, Podgoreanu MV, Phillips-Bute B, Mathew JP, Smith PK, Newman MF, Schwinn DA, Stafford-Smith M. Genetic factors contribute to bleeding after cardiac surgery. J Thromb Haemost 2005;3:1206-12 (Pubitemid 41725243)
204. Clements RT, Smejkal G, Sodha NR, Ivanov AR, Asara JM, Feng J, Lazarev A, Gautam S, Senthilnathan V, Khabbaz KR, Bianchi C, Sellke FW. Pilot proteomic profile of differentially regulated proteins in right atrial appendage before and after cardiac surgery using cardioplegia and cardiopulmonary bypass. Circulation 2008;118:S24-31